Exchange: NASDAQ·Updated 07:30 PM EST
XFOR logo

XFOR X4 Pharmaceuticals Inc

$2.84
$0.29
(9.29%)
Today
Closed $2.83
$0.01
(0.35%)
After Hours
Reported EarningsNov 4
Mkt Cap$318.59M
Vol672,576.00

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
48

Neutral Sentiment

How do you feel about XFOR?

Pope25
$XFOR extreme lack of hype around the upcoming investor call and the fact Craig just bought shares on open market
3
TwongStocks
$XFOR 10-Q filed with the SEC after hours https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169726000089/xfor-20260930.htm • 102,113,554 shares outstanding as of Nov 2. • $187.7M in cash & cash equivalents as of Sept 30. This does not include proceeds from the Loan Agreement with K2 HealthVentures signed Oct 7. • 4WARD trial still expected to complete enrollment by end of 2026. • Xolremdi net product revenue $2.8M last qtr.
1

Advertisement|Remove ads.